ZYBTNasdaq

Zhengye Biotechnology Holding Ltd

Healthcare·Healthcare·Jilin, China

Zhengye Biotechnology Holding Ltd (ZYBT): ~3 mo cash runway. Updated within the last hour.

4.6/10

BioSniper Score

2-factor signal · derived from public data

Cash Runway0.7

2.5 months

Financial Health8.4

D/E 0.52

Pipeline MaturityN/A

N/A

Pipeline BreadthN/A

N/A

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Zhengye Biotechnology Holding Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$38.2M

Cash

$7.2M

Quarterly Burn

$13.5M

Runway

2.5 mo

Revenue

$16.6M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2026
Today~7 mo out
Catalyst within runway

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

5

Total value held

$101K

HolderSharesValue
xtx topco ltd44,146$41K
winton group ltd33,389$31K
geode capital management, llc29,068$27K
royal bank of canada1,230$1K
morgan stanley261$244
·CEO: Mr. Songlin Song

Frequently asked questions

What is Zhengye Biotechnology Holding Ltd's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Zhengye Biotechnology Holding Ltd has approximately 2.5 months of cash runway.

What is Zhengye Biotechnology Holding Ltd's market capitalization?

Zhengye Biotechnology Holding Ltd's market capitalization is approximately $38.2M.

Who is the CEO of Zhengye Biotechnology Holding Ltd?

Mr. Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Ltd (ZYBT).

Get the full picture on Zhengye Biotechnology Holding Ltd

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.